Galapagos NV (GLPG) Surges on License Deal; KaloBios Pharma (KBIO) Crashes On Shkreli’s Arrest


Galapagos NV (Nasdaq:GLPG) stock surged on Thursday’s trading session after the company said that it will receive a $725 million upfront payment from the pharmaceutical giant Gilead Sciences, Inc. (Nasdaq:GILD) as part of a collaboration deal between the companies for the inflammatory disease treatment filgotinib. Galapagos is also eligible for up to $1.35 billion in milestones payments

GLPG stock is currently exchanging hands for about $61.28, up $2.38 (or +4.04%), and 271,663 of its shares were traded so far, a large increase in activity versus its average volume (3m) of 128,202

Galapagos NV, a clinical-stage biotechnology company, has 39.01M Shares Outstanding and GLPG stock 52-week range is from $38.04 to $65.70 per share



Shares of KaloBios Pharmaceuticals, Inc. (Nasdaq:KBIO) tumbled more than 50% in pre-market trading Thursday following media reports indicating that the company’s CEO Martin Shkreli was arrested by the FBI on securities fraud charges. Trading in KaloBios’ stock is currently halted

KaloBios Pharmaceuticals, a biopharmaceutical company, has 4.12M Shares Outstanding and KBIO stock one-year range is between $0.44 and $45.82 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at